Trial site
Goryokai Medical Corporation - Goryokai Hospital
Sapporo, Hokkaido 002-8029, JapanNot linked to an institution yet
The trials here
What the 6 trials at this site are about, from their registry records.
- Lead sponsor
- Bristol-Myers Squibb5 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
Running trials
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Kimihiro Nakajima, Site 0073
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567· Phase 3· Bristol-Myers Squibb· Source
Contact: Kimihiro Nakajima, Site 0073
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Kimihiro Nakajima, Site 0108
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Kimihiro Nakajima, Site 0005
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· Phase 3· Bristol-Myers Squibb· Source
Contact: Kimihiro Nakajima, Site 0080
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT06882785· Phase 3· Bristol-Myers Squibb· Source
Contact: Kimihiro Nakajima, Site 0004
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error